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Abstract

Background
Population-based cancer survival is one of the important measures of the overall effectiveness of cancer care in a population. Population-based cancer registries collect data that enable the estimation of cancer survival. To ensure accurate, consistent and comparable survival estimates, strict control of data quality is required before the survival analyses are carried out.
In this paper, we present a basis for data quality control for cancer survival.
Methods
We propose three distinct phases for the quality control. Firstly, each individual variable within a given record is examined to identify departures from the study protocol; secondly, each record is checked and excluded if it is ineligible or logically incoherent for analysis; lastly, the distributions of key characteristics in the whole dataset are examined for their plausibility.
Results
Data for patients diagnosed with bladder cancer in England between 1991 and 2010 are used as an example to aid the interpretation of the differences in data quality. The effect of different aspects of data quality on survival estimates is discussed.
Introduction
Population-based cancer survival is one of the important measures of the overall effectiveness of cancer care and control in a population, alongside incidence and mortality. Trends in cancer survival provide further indication of improvements in diagnosis and treatment. 1 Standard checks required for cancer incidence data have been described [2] [3] [4] and are embodied in the widely used IARC Check program. 5 However, additional quality checks are required for survival analysis, as the completeness and validity of data on vital status (alive, dead or lost to follow up) and follow-up time of the patients become crucial.
The interpretation of survival comparisons between countries or populations (defined by calendar period, socio-economic status, race or ethnicity) relies on the thoroughness of quality control procedures, which ensure that incomplete, ineligible or incoherent tumour records are flagged and excluded. We describe a set of quality control procedures that have been applied to population-based data for several recent national and international studies of cancer survival. [6] [7] [8] [9] This set of procedures can form a basis for data quality control in cancer survival analysis.
Materials and Methods
Cancer registry data
Cancer registries collate data from sources such as hospitals, general practitioners, pathology departments, cancer referral units and screening programmes, and obtain one record for each tumours including patient demographic (date of birth, sex, residence or postcode, ethnicity, patient identifier), tumour (date of diagnosis, topography, morphology, behaviour, microscopic confirmation, stage at diagnosis), treatment (surgical procedure, chemotherapy, radiotherapy) and outcome (date and place of death) data. 10, 11 This process may not be completed for six to nine months, until a patient's course of treatment has finished.
Information on the patient's vital status is later added from sources such as the regional or national death indexes, social security, health insurance, death certificates, physician or hospital contacts and/or home visits. The key concern is that the eventual deaths of all registered cancer patients are recorded. The quality and completeness of this information is essential for accurate estimation of survival.
Defining the cancers
Cancers are defined by their anatomic location (site) and microscopic appearance (morphology), and whether they are benign, in situ, malignant or of uncertain behaviour (behaviour), under the International Classification of Diseases 12 or the International Classification of Disease for Oncology. 13 Various utilities exist to convert ICD codes between the various revisions. 14, 15 In what follows, we write from the perspective of a general cancer registry, with data on all cancers.
Quality control
Quality control procedures are designed to ensure that survival analyses include only patients resident in the defined territory who were diagnosed with a primary, invasive, malignant neoplasm during a defined calendar period, and whose tumour record is valid and logically coherent. 16 We propose three distinct phases for the quality control of cancer data for survival analysis (Figure 1 ). In the following sections, we will describe the rationale and process for each of these phases with accompanying examples. As any data quality control process, feedback is provided to the data sources, i.e. the registries, which will result to data checks and may lead to modifications. In a study involving several registries, quality control would entail discussion between the analytic centre and the registry concerned.
Phase 1: Protocol adherence (variables)
Are the individual variables within a given record compliant with protocol? A protocol specifies all permissible values for each variable, 9 such as last known vital status: alive=1, dead=2, lost to follow-up=3, unknown=9 ( Table 1 ), or that the month of a date is in the range 1-12. Protocol adherence involves checking each variable in each record to confirm that its value falls within the specified range, and tabulating the number and proportion of variables that meet the protocol definitions ( Table 2 ). Records containing variables that are not compliant with protocol should be reviewed for correction or re-coding. Data sets with substantial proportions of error will require further detailed checks by the cancer registry concerned.
Phase 2: Eligibility and exclusion (records)
Are the variables in each record eligible and logically coherent for analysis? We recommend a two-stage selection process (Table 3) .
Tumour records in the raw data are first selected as eligible for analysis only if they are for an invasive, primary, malignant neoplasm diagnosed during the period defined for analysis in a patient who was resident in the territory covered by the registry. In situ, non-malignant or secondary tumours should be excluded.
Next, each eligible tumour record is checked for internal logical coherence and validity for inclusion in survival analyses. Such checks include that the day, month and year of each date are coherent, the sequence of dates is plausible (e.g. diagnosis precedes or is equal to the date of death), that the vital status and sex are both known, and that the cancer was not registered only from a death certificate (death-certificate-only, or DCO) or from an autopsy. Duplicate registrations, synchronous tumours and second (third, etc.) primary cancers (often referred to as multiple primary tumours) at the same anatomic site are also excluded. However, we recommend retention in the analyses of eligible multiple primary tumours which are not at the same anatomic site as an earlier tumour. 17, 18 From a practical perspective, automated programs embodying the criteria mentioned above are applied. Each tumour record is checked against both the ineligibility and exclusion criteria, and assigned one or more error flags, as applicable. All records that fail one or more criteria are then excluded from the data in a defined sequence of descending severity, applying the most basic reasons for exclusion first. Counts are made of the number of tumour records that fail each criterion, and a separate count is made of the number and proportion of patients excluded from the data on the basis of each criterion. The results can be presented in standard tables to facilitate examination of data quality. The tables show the total number of records in the raw data, the number that remain after removal of ineligible records, the number (and proportion of eligible patients) excluded because the tumour record failed one or more criteria, and finally the number of patients whose data can be included in survival analysis. The results of this process would lead to review and revision of the data if errors are
confirmed. An example is shown in Table 4 , based on the data preparation for a recent analysis to produce the official National Statistics for cancer survival in England. 19 It is particularly important to check the dates and their sequence in each tumour record.
Complete dates (day, month, year) should be used in survival analysis, because estimates of survival are otherwise biased, particularly for short-term survival. 20 Individual dates should be checked for validity (e.g. 31 February is invalid). The sequence of the dates of birth, diagnosis and last known vital status must also be logically coherent (see Table 3 ). Records with the date of diagnosis outside the predefined range should be excluded. Similarly, records with the date of last known vital status after the predefined end of follow-up (and before the date of data extraction) should be censored as alive at the date of end of follow-up. The distribution of the day and month of each date should also be examined. For example, peaks of distribution of certain values (e.g. 15 for days) reflect high proportion of imputed dates.
Phase 3: Distribution of key characteristics -editorial tables (data sets)
Editorial tables are used to examine aspects of data quality in the data file as a whole. For example, one should examine the number and proportion of DCO registrations over time and the distribution of cancers by deprivation or ethnicity over time. These tables are useful in examining the data for a single registry, but also in comparing the data sets for many registries ( Table 5 ).
The Exclusion and editorial tables are shared with the registry, both to help identify improbable distributions of variables, and to document trends in data quality over time. For studies with more than one cancer registry, such tables provide valuable comparative information.
Results
Data quality control processes help to shed light on observed survival differences between geographical regions and over time periods. Differences in the proportion of tumour records that were eligible for survival analyses could reflect differences in data quality or in diagnostic and coding practices. This change would not be reflected at the protocol adherence phase, as there is no change in the range of morphology codes for bladder cancer. However, the change in coding practice can be faithfully represented in the exclusion table (Table 4 This change would produce an artificial downward trend in bladder cancer survival, without any real change in survival times for patients with genuinely invasive malignancy. It would produce a downward trend in bladder cancer incidence, but would not influence observed mortality. Regional variations in survival and incidence within England may also be explained by this change in practice; the change in coding practice happened gradually in the different regional cancer registries between 1986 and 1999. 23 Data quality control processes can thus highlight potential artefacts in the data that can inform the interpretation of survival estimates.
Interpretation of differences in data quality
Potential differences and changes in the quality of cancer registration can also be evaluated.
For bladder cancer in England, the number of DCO registrations decreased from 4.3% in 1991 to 1.8% in 2010 (Table 4) , which reflects an improvement in the quality of cancer registration in England. Similarly, data quality difference between registries can be assessed by the completeness and validity of vital statistics information and by the proportion of records with DCOs.
Other factors can also influence the comparability and continuity of registration data for survival analyses. For example, introduction of screening programmes (e.g. for breast cancer)
allows the detection of a high proportion of low stage cancers, which would result in an increase in cancer survival estimates. The exclusion and editorial output from the data quality control process would offer an insight to these changes. Survival trends should also be interpreted alongside trends in incidence and mortality.
Discussion
This paper provides an overview of the data quality control methods currently used by the Cancer Research UK Cancer Survival Group to prepare population-based cancer registry data for the estimation of cancer survival. We recommend application of strict data quality control procedures to ensure internally valid and externally comparable survival estimates. This monitoring of quality control methods is a continuous process. 5 It involves routine checking for validity and consistency, and maintenance and updating of the cleaning programmes that are used to identify and flag inconsistencies or possible errors, and to present the results in suitable tables and graphics.
It is impossible to be completely prescriptive about all the quality-control tests that should be conducted before analysis of survival in a given data set. For example, if the analyses will involve examination of survival by stage at diagnosis, it will be necessary to perform tests of the completeness and validity of the data on stage, and perhaps to perform multiple imputation for missing values of stage. The range of tests to be performed will also depend on the variables that are collected by the cancer registry concerned; and in the case of a comparative analysis involving several registries, on the variables included in the study protocol.
However, several key variables required for population-based survival analyses must be completely and accurately recorded in the registry for accurate estimation of survival. For example, if follow-up for patient's vital status is not complete and deaths are not all recorded properly (error in the 'vital status' variable), patients may become 'immortals' (Table 5 ) and over-estimation of survival would occur. In this case, a cleaning process which allows the identification of probable 'immortals' would be essential for estimating the scale of the problem. Ideally, full dates of birth, dates of diagnosis and dates of follow-up should always be used to ensure complete data assessment and unbiased survival estimation. 20 By contrast, we recommend inclusion in survival analyses of patients who died on the same day as the diagnosis of their cancer. It may be necessary to assume for these patients that death occurred one day after diagnosis, if the statistical software cannot deal with zero survival time. Excluding such observations would artificially over-estimate survival.
Cancer registrations based solely on a death certificate (death-certificate-only or DCO registrations) are assigned to the date of death for the purposes of cancer incidence, but they cannot be included in survival analyses 24 because the duration of survival is unknown. If
DCOs represent a high proportion of all registered cases, this suggests under ascertainment of incident cases. If the true (but unknown) duration of survival for patients registered as a DCO is shorter than the average, a high proportion of DCO cases may also lead to over-estimation of survival. 25 The proportion of DCOs will be zero in countries where death certificates are not used to initiate a new cancer registration or where access to the cause of death is not legal; this may give rise to some under registration of incident cases. By contrast, it is generally advisable to include a person with two malignancies that have occurred at different anatomic sites in the analysis of survival for each of the sites. Including multiple primaries at different sites reduces the bias in comparison of survival between registries due to different observation periods, age, registration quality and completeness of registration. 18 For example, if we were to exclude them, a subsequent cancer of a patient would be excluded in a registry with records of the first cancer, while it would be treated as the first cancer in a younger registry and included in survival analyses; this would bias survival comparisons. Including multiple primary tumours also avoids the conceptual difficulties that arise from the definition of multiple primary malignancy, which differs widely between the two main sets of international rules (SEER and IARC). 26, 27 The general effect of inclusion is to reduce survival estimates by a variable amount depending on the proportion of multiple primaries, the cancer site, and the extent to which survival for subsequent tumours is shorter than for first primary tumours. 17 One final caveat, which is that if we are to analyse survival from all cancers combined, in which we pool the data from more than one anatomic site as typically defined, then it would again become inappropriate to include a single person more than once in the analyses, which should then be confined to first primary malignancies.
We recommend consistent application of data quality checks in preparing population-based data for the estimation of cancer survival, in order to ensure accuracy, consistency and comparability of the estimates. The data quality assurance procedures should be reported when presenting the results of survival analyses, in order to facilitate their interpretation.
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